US009636335B2

(12) **United States Patent**
Nirogi et al.

(10) **Patent No.: US 9,636,335 B2**
(45) **Date of Patent: May 2, 2017**

(54) **HETEROARYL COMPOUNDS AS 5-HT$_4$ RECEPTOR LIGANDS**

(71) Applicant: **Suven Life Sciences Ltd**, Hyderabad, Andhra Pradesh (IN)

(72) Inventors: **Ramakrishna Nirogi**, Andhra Pradesh (IN); **Abdul Rasheed Mohammed**, Andhra Pradesh (IN); **Suresh Yarlagadda**, Andhra Pradesh (IN); **Srinivasa Rao Ravella**, Andhra Pradesh (IN); **Anil Karbhari Shinde**, Andhra Pradesh (IN); **Ramasastri Kambhampati**, Andhra Pradesh (IN); **Praveen Kumar Roayapalley**, Andhra Pradesh (IN); **Pradeep Jayarajan**, Andhra Pradesh (IN); **Gopinadh Bhyrapuneni**, Andhra Pradesh (IN); **Sriramachandra Murthy Patnala**, Andhra Pradesh (IN); **Jyothsna Ravula**, Andhra Pradesh (IN); **Venkateswarlu Jasti**, Andhra Pradesh (IN)

(73) Assignee: **SUVEN LIFE SCIENCES LIMITED**, Hyderabad (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/735,237**

(22) Filed: **Jun. 10, 2015**

(65) **Prior Publication Data**

US 2015/0283125 A1 Oct. 8, 2015

Related U.S. Application Data

(62) Division of application No. 13/982,486, filed as application No. PCT/IN2012/000011 on Jan. 5, 2012, now Pat. No. 9,079,894.

(30) **Foreign Application Priority Data**

Sep. 19, 2011 (IN) 3203/CHE/2011

(51) **Int. Cl.**

A61K 31/445	(2006.01)
A61K 31/454	(2006.01)
C07D 413/14	(2006.01)
C07D 413/06	(2006.01)
A61K 31/4245	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/454*** (2013.01); ***A61K 31/4245*** (2013.01); ***C07D 413/06*** (2013.01); ***C07D 413/14*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,854,261 A	12/1998	Bosmans	514/320
7,943,645 B2	5/2011	Chan et al.	514/364
2006/0194842 A1	8/2006	Uchida	
2008/0207690 A1	8/2008	Noguchi	
2008/0255113 A1	10/2008	Kato	
2008/0269211 A1	10/2008	Ishibashi	

FOREIGN PATENT DOCUMENTS

WO	WO 93/02677 A1	2/1993
WO	9717345	5/1997

OTHER PUBLICATIONS

Karran, E. et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature. 2011, vol. 10, p. 698.*

Schmitz, C. et al. Hippocampal Neuron Loss Exceeds Amyloid Plaque Load in a Transgenic Mouse Model of Alzheimer's Disease. American Journal of Pathology. 2004, vol. 164, p. 1495.*

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association. 2000, pp. 885-886.*

Bostrom, J. et al. Oxadiazoles in Medicinal Chemistry. Journal of Medicinal Chemistry. 2012, vol. 55, p. 1817.

J. Bockaert et al., "5-HT4 Receptors" Current Drug Targets—CNS & Neurological Disorders 3:39-51 (2004).

S. Consolo et al., "5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex" NeuroReport 5:1230-1232 (1994).

C.J. Swain et al., "Novel 5-HT3 Antagonists. Indole Oxadiazoles" J. Med. Chem. 34:140-151 (1991).

Brown, Arthur M. and Rampe, David, "Drug-Induced Long QT Syndrome: Is HERG the Root of All Evil", Pharmaceutical News, Published 2000, pp. 15-20, vol. 7, No. 4.

Beattie, D.T., et al, "An In Vitro Investigation of the Cardiovascular Effects of the 5-HT 4 Receptor Selective Agonists, Velusetrag and TD-8954", Vascular Pharmacology (2012) pp. 1-28 doi:10.1016/j.vph.2012.11.002.

Langlois, Michel & Fischmeister, Rodolphe, "5-HT4 Receptor Ligands: Applications and New Prospects", Journal of Medicinal Chemistry, Published 2003, pp. 319-44, vol. 46, No. 3.

Letty, S., et al, "5-HT4 Receptors Improve Social Olfactory Memory in the Rat", Neuropharmacology, published 1997, pp. 681-687, vol. 36, No. 4/5.

(Continued)

Primary Examiner — Noble Jarrell

Assistant Examiner — Ben S Michelson

(74) *Attorney, Agent, or Firm* — Iphorgan Ltd.

(57) **ABSTRACT**

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them.

(I)



The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT$_4$ receptors.

21 Claims, No Drawings